BIO 2026: Cell and gene therapy sector must break the mold to thrive on June 22, 2026 Access Bio Cells commercial gene therapy manufacturing regulatory scalability Viable +
Strengthening Payer Engagement with Real-World Evidence: Recent Developments on May 01, 2026 Access Evidence Healthcare Payers Market patient outcomes Payer Engagement real-world Real-world Evidence +
Unlocking Access: Navigating Pharma’s Regulatory Crossroads – Recent Updates (2025) on October 15, 2025 Access access strategy Biosimilars CRLs drug importation drug price executive actions Market Patient access pharmaceutical regulation United States Food and Drug Administration +
DTC vs. DTP: Regulatory Uncertainty & Access Challenges Drive New Go-to-Market Models (2025 Update) on July 29, 2025 Access Diphtheria-Tetanus-Pertussis Vaccine direct-to-consumer direct-to-patient Ditiocarb go-to-market models pharmaceutical marketing regulatory uncertainty United States Food and Drug Administration +
Novo Nordisk taps telehealth giants to distribute Wegovy, sending shares soaring on April 30, 2025 Access Adult CALR gene LifeMD Nordisk Obesity semaglutide Telemedicine Wegovy +
Drug pricing watchdog ICER offers ways to increase obesity drug access on April 09, 2025 Access drug price ICER Obesity Policy Wegovy +
Six Payer Trends Shaping Market Access in 2025 on March 14, 2025 2025 Access Artificial Intelligence Enrollment Market payer payers Shapes trends qualifier +
Six Payer Trends Shaping Market Access in 2025 on March 13, 2025 Access coverage - financial contract Market payers trends qualifier +
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch on February 27, 2025 Access EU Failed Market NR4A2 gene +